

August 10, 2016



# Endonovo Therapeutics Files Patent for Treating Chemical and Radiation Injuries Using Next-Generation Biologics

## Next-Generation Biologics Include Cell Therapies and Human Biomolecules Produced by Electromagnetic Stimulation of Adult Stem Cells

LOS ANGELES, CA -- (Marketwired) -- 08/10/16 -- [Endonovo Therapeutics, Inc.](#) (OTCQB: ENDV), a developer of bioelectronic devices and non-invasive Electroceuticals for the treatment of inflammatory conditions in vital organs, announced today that it has filed a patent titled, "Methods and Compositions for Treating Chemical and Radiation Injuries." The patent filing covers the production of biologics, including cell therapies and biomolecules created using a proprietary bioreactor and their corresponding administration as a therapeutic for treating chemical and radiation injuries, including chemotherapy and radiation exposure.

This patent filing is a continuation-in-part of the patent described in the announcement dated August 9, 2016.

Next-Generation Biologics, including growth factors and cell therapies seek to overcome the shortcomings of current therapies, including inconvenient dosing, immunogenicity and other side effects. [Visiongain](#) predicts a market for next-generation biologics of \$30 billion with five blockbuster biologics being developed by the year 2024.

Alan Collier, Endonovo's Chief Executive Officer, commented, "Now that we have an issued patent covering our proprietary process, which effectively trains cells to secrete therapeutic proteins, such as G-CSF, GM-CSF, EPO and IL-2, we can begin pursuing several indications using our Cytotronics platform."

"Many of the biomolecules that we can train cells to produce are used to promote the growth of specific blood cells, including, blood-forming stem cells, infection-fighting white blood cells and oxygen carrying red blood cells. We believe that we can also expand blood-forming stem cells to replace damaged or lost cells and train and enhance them using our proprietary process to deliver a cocktail of therapeutic proteins," said Mr. Collier.

### ***About Endonovo Therapeutics***

Endonovo Therapeutics, Inc. is a leading developer of bioelectronic-applications in cell therapies and non-invasive Electroceuticals™. Endonovo's Immunotronics™ platform is dedicated to treating patients with life-threatening inflammatory conditions, such as acute liver injury and fulminant hepatic failure, using proprietary non-invasive Electroceutical™

devices. The Company's non-invasive platform is based on magnetically-induced electrical field pathways that target inflammation and cell death.

The Company's Cytotronics™ platform harnesses the bulk electrical properties of cells and tissues, namely magnetically-induced electrical field pathways to expand and enhance the therapeutic potential of cell therapies and produce next-generation biologics.

### ***Safe Harbor Statement***

This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release including words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company's estimates as of the date of the press release, and subsequent events and developments may cause the Company's estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company's estimates of its future financial performance as of any date subsequent to the date of this press release.

Investors: [Sign Up for Email Alerts](#) on Endonovo

### ***Investor Relations Contact:***

Endonovo Therapeutics, Inc.

Mr. Steven Barnes

Senior Vice President of Investor Relations

(800) 701-1223, Ext. 108

[Sbarnes@endonovo.com](mailto:Sbarnes@endonovo.com)

[www.endonovo.com](http://www.endonovo.com)

Source: Endonovo Therapeutics, Inc.